Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 17.

Suchorska, B; Weller, M; Tabatabai, G; Senft, C; Hau, P; Sabel, M C; Herrlinger, U; Ketter, R; Schlegel, U; Marosi, C; Reifenberger, G; Wick, W; Tonn, J C; Wirsching, H G (2016). Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro-Oncology, 18(4):549-556.

Hoang-Xuan, K; Bessell, E; Bromberg, J; Hottinger, A F; Preusser, M; Rudà, R; Schlegel, U; Siegal, T; Soussain, C; Abacioglu, U; Cassoux, N; Deckert, M; Dirven, C M; Ferreri, A J; Graus, F; Henriksson, R; Herrlinger, U; Taphoorn, M; Soffietti, R; Weller, M (2015). Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncology, 16(7):e322-332.

Korfel, A; Thiel, E; Martus, P; Möhle, R; Griesinger, F; Rauch, Mi; Röth, A; Hertenstein, B; Fischer, T; Hundsberger, T; Mergenthaler, H G; Junghanß, C; Birnbaum, T; Fischer, L; Jahnke, K; Herrlinger, U; Roth, P; Bamberg, M; Pietsch, T; Weller, M (2015). Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology, 84(12):1242-1248.

Weller, Michael; Tabatabai, G; Kästner, B; Felsberg, J; Steinbach, J P; Wick, A; Schnell, O; Hau, P; Herrlinger, U; Sabel, M C; Wirsching, H G; Ketter, R; Bähr, O; Platten, M; Tonn, J C; Schlegel, U; Marosi, C; Goldbrunner, R; Stupp, R; Homicsko, K; Pichler, J; Nikkhah, G; Meixensberger, J; Vajkoczy, P; Kollias, S; Hüsing, J; Reifenberger, G; Wick, W (2015). MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research, 21(9):2057-2064.

Patrij, K; Reiser, M; Wätzel, L; Pels, H; Kowoll, A; Herrlinger, U; Engert, A; Linnebank, M; Schackert, G; Vogt-Schaden, M; Egerer, G; Lamprecht, M; Batchelor, T T; Schlegel, U; Schmidt-Wolf, I G H (2011). Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis. German Medical Science, 9:Doc11.

Glas, M; Bähr, O; Felsberg, J; Rasch, K; Wiewrodt, D; Schabet, M; Simon, M; Urbach, H; Steinbach, J P; Rieger, J; Fimmers, R; Bamberg, M; Nägele, T; Reifenberger, G; Weller, M; Herrlinger, U (2011). NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Annals of Neurology, 70(3):445-53.

Weiler, M; Hartmann, C; Wiewrodt, D; Herrlinger, U; Gorlia, T; Bähr, O; Meyermann, R; Bamberg, M; Tatagiba, M; von Deimling, A; Weller, M; Wick, W (2010). Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. International Journal of Radiation Oncology, Biology and Physics, 77(3):670-676.

Kurzwelly, D; Glas, M; Roth, P; Weimann, E; Lohner, H; Waha, A; Schabet, M; Reifenberger, G; Weller, M; Herrlinger, U (2010). Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. Journal of Neuro-Oncology, 97(3):389-392.

Kurzwelly, D; Knop, S; Guenther, M; Loeffler, J; Korfel, A; Thiel, E; Hebart, H; Simon, M; Weller, M; Linnebank, M; Herrlinger, U (2010). Genetic variants of folate and methionine metabolism and PCNSL incidence in a German patient population. Journal of Neuro-Oncology, 100(2):187-192.

Thiel, E; Korfel, A; Martus, P; Kanz, L; Griesinger, F; Rauch, M; Roth, A; Hertenstein, B; von Toll, T; Hundsberger, T; Mergenthaler, H G; Leithäuser, M; Birnbaum, T; Fischer, L; Jahnke, K; Herrlinger, U; Plasswilm, L; Nägele, T; Pietsch, T; Bamberg, M; Weller, M (2010). High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncology, 11(11):1036-1047.

Juergens, A; Pels, H; Rogowski, S; Fliessbach, K; Glasmacher, A; Engert, A; Reiser, M; Diehl, V; Vogt-Schaden, M; Egerer, G; Schackert, G; Reichmann, H; Kroschinsky, F; Bode, U; Herrlinger, U; Linnebank, M; Deckert, M; Fimmers, R; Schmidt-Wolf, I G H; Schlegel, U (2010). Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Annals of Neurology, 67(2):182-189.

Glas, M; Happold, C; Rieger, J; Wiewrodt, D; Bähr, O; Steinbach, J P; Wick, W; Kortmann, R; Reifenberger, G; Weller, M; Herrlinger, U (2009). Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide. Journal of Clinical Oncology, 27(8):1257-1261.

Bähr, O; Herrlinger, U; Weller, M; Steinbach, J P (2009). Very late relapses in glioblastoma long-term survivors. Journal of Neurology, 256(10):1756-1758.

Kurzwelly, D; Müller, C A; Korfel, A; Thiel, E; Linnebank, M; Weller, M; Herrlinger, U (2008). Primary CNS lymphoma and HLA class I and II alleles in a German cohort of immunocompetent patients. Journal of Neuro-Oncology, 90(1):53-55.

Waerzeggers, Y; Klein, M; Miletic, H; Himmelreich, U; Li, H; Monfared, P; Herrlinger, U; Hoehn, M; Coenen, H H; Weller, M; Winkeler, A; Jacobs, A H (2008). Multimodal imaging of neural progenitor cell fate in rodents. Molecular Imaging, 7(2):77-91.

Glas, M; Rasch, K; Wiewrodt, D; Weller, M; Herrlinger, U (2008). Procarbazine and CCNU as initial treatment in gliomatosis cerebri. Oncology, 75(3-4):182-185.

Jacobs, A H; Rueger, M A; Winkeler, A; Li, H; Vollmar, S; Waerzeggers, Y; Rueckriem, B; Kummer, C; Dittmar, C; Klein, M; Heneka, M T; Herrlinger, U; Fraefel, C; Graf, R; Wienhard, K; Heiss, W-D (2007). Imaging-guided gene therapy of experimental gliomas. Cancer Research, 67(4):1706-1715.

This list was generated on Mon Nov 20 16:18:22 2017 CET.